20/20 Onsite, Boston, MA (2026)

02/25/2026

Site Initiation Visits (SIVs) are where ocular endpoints either get set up for clean, consistent ex*****on, or quietly pick up the “small problems” that turn into timeline slips, data variability, and avoidable rework later.

A few SIV focuses that matter more than most teams expect:

- Training and certification: BCVA, OCT, IOP, these are not “plug and play.” Standardization is the work.
- Device validation and readiness: calibration, documentation, and traceability need to be audit-ready from day one.
- Vendor coordination and data flow: if device data to CRF/EDC is not mapped early, you will feel it at go-live.

If you are building in ocular endpoints, treat the SIV as your operational design review, not a checkbox.

Read the full breakdown here. https://hubs.ly/Q041h4L70

02/19/2026

The shift toward decentralized trial models surfaces a fundamental tension: ophthalmic endpoints require precision equipment and controlled conditions, yet participant-centric design demands flexibility and reduced burden.

This isn't a tradeoff you solve by compromising on one side.

Virtual-only approaches introduce measurement variability that regulatory bodies scrutinize. Traditional fixed-site models create participation barriers that undermine enrollment and retention targets.

The strategic middle ground is distributed clinical infrastructure, mobile units that bring laboratory-grade conditions to participants rather than asking participants to reach laboratories.

What this requires operationally:
→ Endpoint mapping to identify which assessments demand-controlled environments
→ Equipment standardization across all deployment locations
→ Technician certification that ensures procedural consistency
→ Documentation systems designed for regulatory audit trails

The implementation complexity is real. But so is the enrollment of velocity when you remove the burden of repeated distant travel from protocol participation.

And retention metrics shift substantially when participants experience research as something designed around their lives rather than something that disrupts them.

The question for sponsors isn't whether to decentralize. It's how to decentralize while maintaining the measurement integrity that phase 3 endpoints require.

Framework details: https://hubs.ly/Q03ZQyZv0

02/18/2026

Meet Dr. Kamrian Wilson and Dr. Aubrey Wilson, a mother-daughter optometry duo bringing care, compassion, and a shared passion for patients to 20/20 Onsite's clinical trial network in Missouri.

Dr. Kamrian Wilson's Story:
"I first became involved with 20/20 Onsite when Dr. Alina Reznik reached out on ODs on Facebook asking whether anyone in the Dixon, Missouri area was able to see a child for any ocular evaluation. My practice is just 20 minutes away so I responded, I would be happy to help! I was paid for this, but I would have done it at no charge if needed, just to help this patient remain on a life changing medication."

What keeps her coming back?
"I love working with 20/20 Onsite! The team, including doctors, ophthalmic technicians, and others, are wonderful and passionate about what they do!"

Her philosophy on clinical trial work?
"I feel to work in clinical trials, beyond performing excellent eye care, is a passion for the profession but most importantly a passion for each individual you see."

Dr. Aubrey Wilson's Story:
Following in her mother's footsteps, Dr. Aubrey Wilson joined the 20/20 Onsite network:
"My mom, Kami Wilson, recommended the job to me. It sounded like a great experience to add to my regular job."

What does she love most about the work?
"Getting to meet a variety of patients in an environment with less time pressure. I also enjoyed the free time between patients."

Her most memorable experience captures the heart of family legacy:
"Meeting a patient who had last been examined by my mom Kami, and the patient remembering her. We had a great experience talking together that day."

The Wilson family story reminds us that 20/20 Onsite's OD Network is more than just flexible work; it's meaningful work worth recommending to the people you care about most.

Are you an OD looking for:
+ Flexible opportunities that complement your existing practice
+ Meaningful work helping patients access life-changing medications
+ A supportive, passionate team environment
+ The chance to make a real difference in clinical research

📩 Interested in learning more? Email Dr. Katherine Harkins, Director of Optometry, at kharkins@2020onsite.com

02/16/2026

Ask any Clinical Ops lead what slows a study and most will say the same thing: enrollment.

📊 9 out of 10 clinical trials ultimately double their original timelines just to meet enrollment targets (Antidote).

It’s not for lack of effort - it’s logistics. Travel burdens, missed screenings, delayed site activations. It all adds up fast.

At 20/20 Onsite, we remove those barriers. Our nationwide, Mobile Vision Clinics bring advanced, point-of-need ocular assessments directly to patients.

That means faster screenings, smoother enrollment, and studies that stay on schedule.

02/12/2026

February is AMD Awareness Month

20 Million Americans. One Leading Cause of Vision Loss.

Age-Related Macular Degeneration (AMD) remains a critical focus in ophthalmology research, and February marks AMD and Low Vision Awareness Month.

As clinical trials advance new AMD treatment options, precise retinal imaging isn't just important, it's mission-critical.

Why AMD Trials Demand Imaging Excellence:
✓ Micron-level changes determine treatment efficacy
✓ Protocol deviations risk endpoint integrity
✓ Inconsistent imaging threatens regulatory approval

20/20 Onsite supports AMD research with strategic point-of-need imaging that ensures:
→ FDA-ready data capture
→ Protocol-compliant screening
→ Consistent trial outcomes

Early detection changes lives. Clinical precision changes the future.

Learn more about AMD awareness: https://hubs.ly/Q042KxBs0

02/11/2026

$285 million.

That’s the mean cost of a single Phase III clinical trial (Tufts CSDD).
When that much capital is on the line, every delay, every dropout, every missed visit chips away at ROI.

At 20/20 Onsite, we safeguard that investment.
Our Mobile Vision Clinics deliver high patient retention and 100% on-time screenings — ensuring your study stays on schedule and on budget.

In clinical research, protection isn’t just about data — it’s about dollars.

Safeguard millions. Deliver results.

02/09/2026

Enrollment stalls. Referral bottlenecks. Screen failures mounting.

If your clinical trial is facing ophthalmic assessment challenges, the warning signs are clear and the costs are climbing.

Join Jessica McKenzie, VP of Life Sciences at 20/20 Onsite, for an exclusive on-demand webinar where she reveals the field-tested framework to spot risks early, triage immediately, and protect your critical endpoints.

Watch this webinar to learn how to identify warning signals before they derail your trial timeline.

Watch the webinar now → https://hubs.ly/Q03Zxlq60

02/05/2026

Enrollment stalled. Referral pathways bottlenecked. Screen fiascos are increasing.

These aren't just operational hiccups; they're trial-ending risks that cost approximately $40K per day in direct costs, plus millions in delayed revenue.

Jessica McKenzie, VP of Life Sciences at 20/20 Onsite, has rescued dozens of derailed trials using point-of-need ophthalmic solutions that stabilize protocols and get studies back on track—fast.

Watch this exclusive webinar to see exactly how she's helped 40+ trials maintain 100% timeline compliance, even when facing critical capacity constraints.

Watch the webinar and request your free 24-hour assessment → https://hubs.ly/Q03ZxkQY0

02/04/2026

The first few days at SCOPE Summit 2026 in Orlando reinforced a theme we’re hearing everywhere across clinical operations: patient-centric trials scale faster when innovation is paired with the right partnerships.

A few takeaways that stood out:
+ Strategic innovation partnerships are now a scaling lever: Teams are looking for suppliers who can bring operational lift, not just tools or staffing.
+ Supplier selection is being modernized, but not de-humanized: Automating the intake, comparison, and contracting process matters, but so does keeping real human support in the workflow to guide decisions and unblock ex*****on.
+ Vendor governance and communication are the differentiator: The strongest teams treat vendor relationships as a performance system, not a transaction. When the partnership truly benefits sites and patients, cost becomes secondary.

If you’re at SCOPE this week (at Rosen Shingle Creek), connect with our Life Sciences Account Executive, Katie Sigg, to compare notes on patient-centric ex*****on and how to reduce site burden while protecting endpoints.

DM us to set up a time or use this link: https://hubs.ly/Q041LQV60

02/03/2026

Throughout the year, the Life Sciences team rolls with the Eye Care Team for a full day on one of our Mobile Vision Clinics, greeting patients and jumping in wherever support is needed.

This week was a clear reminder of why that matters. Our team helped support a local school visit, serving a diverse student body where over 90% of students are multilingual learners, ensuring students received high-quality care, including advanced diagnostic testing and imaging.

Proud of the team for responding quickly and staying focused on what matters most — making vision care more accessible.

02/02/2026

Distributed assessment protocols aren't about choosing between participant convenience and measurement accuracy; they're about architecting systems that deliver both.

The implementation framework requires attention to:

→ Endpoint-specific technical requirements
→ Equipment calibration standards
→ Personnel certification protocols
→ Real-time quality oversight

Remote units eliminate travel barriers while maintaining the controlled environments that ophthalmic measurements demand. Certified staff, calibrated instruments, and standardized procedures, delivered to where participants are.

The outcome is faster enrollment, stronger retention, and measurement of reliability that supports regulatory confidence.

Our framework details operational considerations for sponsors designing decentralized protocols with ophthalmic endpoints.

Access it here: https://hubs.ly/Q03Zxjjz0

01/30/2026

Distributed assessment protocols aren't about choosing between participant convenience and measurement accuracy; they're about architecting systems that deliver both.

The implementation framework requires attention to:

→ Endpoint-specific technical requirements
→ Equipment calibration standards
→ Personnel certification protocols
→ Real-time quality oversight

Remote units eliminate travel barriers while maintaining the controlled environments that ophthalmic measurements demand. Certified staff, calibrated instruments, and standardized procedures, delivered to where participants are.

The outcome is faster enrollment, stronger retention, and measurement of reliability that supports regulatory confidence.

Our framework details operational considerations for sponsors designing decentralized protocols with ophthalmic endpoints.

Access it here: https://hubs.ly/Q03_xTC10

20/20 Onsite

02/25/2026

02/19/2026

02/18/2026

02/16/2026

02/12/2026

02/11/2026

02/09/2026

02/05/2026

02/04/2026

02/03/2026

02/02/2026

01/30/2026

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category